(Reuters) - Amgen Inc on Thursday reported higher-than-expected second quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts.
The world's largest biotechnology company said net profit rose to $1.65 billion, or $2.15 per share, from $1.55 billion, or $2.01, a year ago.
Excluding special items, Amgen earned $2.57 per share. Analysts on average expected $2.43 per share, according to Thomson Reuters I/B/E/S.
Amgen now expects 2015 adjusted earnings of $9.55 to $9.80 per share, up from its prior view of $9.35 and $9.65. It also boosted its full-year revenue expectations to between $21.1 billion and $21.4 billion, from $20.9 billion to $21.3 billion.
(Reporting by Bill Berkrot; Editing by Chizu Nomiyama)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app